Refludan

Refludan®

Lepirudin Hematology A recombinant hirudin for treating heparin-induced thrombocytopenia. See Heparin-induced thrombocytopenia.
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.
References in periodicals archive ?
Refludan was obtained from Pharmion (Berlin, Germany).
PRP was centrifuged for 30 min at 1300g and the pellet was resuspended in HBSS with [Ca.sup.2+] and [Mg.sup.2+] (Life Technologies) containing 10% citrate buffer (38 mM citrate, 88 mM sodium citrate) and modified Tyrodes buffer 1 (137 mM sodium chloride, 2.7 mM potassium chloride, 10 mM Hepes [N-2-hydroxyethylpiperazineN0-2-ethanesulfonic acid], 0.36 mM sodium dihydrogen phosphate, 5.5 mM dextrose, pH 6.4) supplemented with 1 U/ml refludan. Platelets were resuspended in HBSS/citrate and FCS-free RPMI medium.
Lepirudin (50 mg; Refludan, Celgene Europe Ltd, Wndsor, United Kingdom) and argatroban (250 mg/2.5 mL; Argatra, Mitsubishi Pharma Deutschland GmbH, Dusseldorf, Germany) were prepared according to the manufacturer's instructions.
Available DTIs include argatroban, lepirudin (Refludan), and bivalirudin (Angiomax).
Heparine bagli trombositopeni oykusu olan hastalarda antikoagulasyon icin hirudin (Refludan), bivalirudin (Hirulog), and argatroban kullanilmaktadir.
After washing, we added 50 [micro]L plasma diluted 1:50 in TBS containing 2 mmol/L Ca[Cl.sub.2], 2 g/L BSA, and 30 nmol/L hirudin (Refludan, Berlex) to the wells and incubated them for 1 h at room temperature.
Reproductive studies of experimental animals with lepirudin (Refludan) at doses 1.2-2.4 times the maximum recommended human dose showed no adverse effect on the fetus.
Lepirudin, which is recombinant hirudin, a specific thrombin inhibitor, is marketed as Refludan.
Aventis had filed an application for approval of the following indication: "anticoagulation in adult patients with acute coronary syndromes (unstable angina/acute MI without ST elevation," followed by the statement: "In this setting, Refludan has been shown to decrease the rate of CV death, new MI, or refractory angina (combined triple end point)."